Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
Blue Cross Blue Shield of Louisiana
|Baton Rouge, LA|
|Senior or Principal Consultant||
|Chief Financial Officer||
Health Alliance Plan of Michigan
|Senior Vice-President Managed Care Mid-Atlantic Region||
Mercy Health System
|Associate Chief Financial Officer||
Commonwealth Care Alliance